Search
Mabwell Biopharmaceuticals, alongside its subsidiary Taikang Biopharmaceuticals, has entered into a Technology License Agreement for New Drug Projects with Qilu Pharmaceutical. Pursuant to this agreement, Mabwell Biopharmaceuticals grants Qilu Pharmaceutical exclusive rights to develop, manufacture, enhance, utilize, and market its novel long-acting G-CSF drug, Agroplatin α for Injection (trade name: Milesheng®, code: 8MW0511), across Greater China. Agroplatin α for Injection leverages albumin long-acting fusion technology, a pioneering domestic innovation. In exchange, Qilu Pharmaceutical will make an initial payment of RMB 380 million, with the potential for up to RMB 500 million in milestone payments, as well as royalties calculated at a double-digit percentage of the net sales of the licensed product.
-
C114 Communication Network -
Communication Home
